Killian Meara

Check out important updates from the FDA for the week of August 19.

Recent research on diabetes has examined its bidirectional relationship with mental health, the significant increase in prevalence over the last decade, and how both diet and exercise can help prevent type 2 diabetes.

Increased incidence of typed 2 diabetes was associated with higher consumption of processed meat, unprocessed red meat, and poultry.

Timothy Mackey, MAS, PhD, discusses a study that sought to determine the risk of sourcing semaglutide from online platforms.

Timothy Mackey, MAS, PhD, discusses the dangers associated with sourcing GLP-1s from illegal online pharmacies and the key role pharmacists play in warning patients.

The approval of apremilast to treat plaque psoriasis in children and adolescents aged 6 years and older was based on data from the phase 3 SPROUT trial.

Focus group participants were receptive to using eHealth tools, but noted several barriers such as cost and availability.

Check out important updates from the FDA for the week of August 12.

Community pharmacies in counties with high racialized economic segregation had higher odds of restricting buprenorphine.

Izokibep from Affibody is a small therapeutic protein designed to inhibit IL-17A.

Medtronic also announced it has entered a global partnership with Abbott in an effort to expand CGM device options for patients living with diabetes.

Rejoyn, developed by Otsuka Pharmaceutical and Click Therapeutics, is only accessible with a prescription from a health care provider.

Two phase 3 trials evaluating nemolizumab found that 41% of patients treated with the therapy achieved at least a 4-point reduction in itch intensity at week 16.

Ascendis Pharma said it is currently completing manufacturing of commercial product, which it anticipates will be available in the US in the first quarter of 2025.

The agency said it could not approve the new drug application based on the submitted data and requested an additional Phase 3 trial to “further study the safety and efficacy” of the therapy.

Check out important updates from the FDA for the week of August 5.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses the implications of a potential FDA approval of MDMA-assisted therapy for PTSD.

Nalmefene injection is an opioid receptor antagonist and comes in a single-dose, pre-filled auto-injector that delivers 1.5 mg of the medication per actuation.

The COVID-19 pandemic led to increased pharmacist burnout and workforce shortages. The impact is still being felt today.

A study found that CT scans of visceral fat had the highest predictive performance of incident diabetes.

A study found that test products purchased from illegal online pharmacy operations had lower purity levels and significantly more semaglutide content than what was advertised on the label.

Finerenone (Kerendia) was previously approved in 2021 to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease associated with type 2 diabetes.

Check out important updated from the FDA for the week of July 29.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Liraglutide slowed the loss of volume in critical brain regions and cognitive decline in patients with mild Alzheimer's dementia.

In 3 Phase 3 trials, elinzanetant reduced the frequency and severity of moderate to severe vasomotor symptoms, and improved sleep disturbances.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

Catch up on important diabetes news from the month of July.

Recent studies on dry eye disease examined the efficacy of Vitamin D, platelet-rich plasma as a treatment option, and associations with certain systemic medications.

Catch up on important dermatology news from the month of July.